1. Advance in microRNA as a potential biomarker for early detection of pancreatic cancer
- Author
-
Gary Guishan Xiao, Jing Huang, Xuemei Zhang, W. N. Paul Lee, Kevin Chen-Xiao, Vay Liang W. Go, and Jianzhou Liu
- Subjects
0301 basic medicine ,Clinical Biochemistry ,Disease ,Review ,Biology ,Signal transduction ,medicine.disease_cause ,Bioinformatics ,Metastasis ,03 medical and health sciences ,0302 clinical medicine ,Cancer stem cell ,Pancreatic cancer ,microRNA ,medicine ,Epigenetics ,Cancer stem cells ,Biochemistry (medical) ,Early detection ,Biomarker ,medicine.disease ,microRNAs ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cancer research ,Molecular Medicine ,Biomarker (medicine) ,Carcinogenesis - Abstract
Pancreatic cancer is characterized as a disease with low survival and high mortality because of no effective diagnostic and therapeutic strategies available in clinic. Conventional clinical diagnostic methods including serum markers and radiological imaging (CT, MRI, EUS, etc.) often fail to detect precancerous or early stage lesions. Development of effective biomarkers is unmet for reduction of mortality of pancreatic cancer. MicroRNAs (miRNAs) are a group of small non-protein-coding RNAs playing roles in regulation of cell physiology including tumorigenesis, apoptotic escape, proliferation, invasion, epithelial-mesenchymal transition (EMT), metastasis and chemoresistance. Various altered signaling pathways involving in molecular pathogenesis of pancreatic cancer are mediated by miRNAs as a role of either oncogenes or tumor suppressors. Among biomarkers developed including protein, metabolites, DNA, RNA, epigenetic mutation, miRNAs are superior because of its unique chemical property. Recent study suggests that miRNAs may be promising biomarkers used for early detection of pancreatic cancer. This review will update the progression made in early detection of pancreatic cancer.
- Published
- 2016